Abstract:Background Systemic therapies have improved the management of hepatocellular carcinoma, but there is still a need to further enhance overall survival in first-line advanced stages. This study aimed to evaluate the addition of pembrolizumab to lenvatinib versus lenvatinib plus placebo in the first-line setting for unresectable hepatocellular carcinoma.Methods In this global, randomised, double-blind, phase 3 study (LEAP-002), patients aged 18 years or older with unresectable hepatocellular carcinoma, Child Pugh class A liver disease, an Eastern Cooperative Oncology Group performance status of 0 or 1, and no previous systemic treatment were enrolled at 172 global sites. Patients were randomly assigned (1:1) with a central interactive voice-response system (block size of 4) to receive lenvatinib (bodyweight <60 kg, 8 mg/day; bodyweight >= 60 kg, 12 mg/day) plus pembrolizumab (200 mg every 3 weeks) or lenvatinib plus placebo. Randomisation was stratified by geographical region, macrovascular portal vein invasion or extrahepatic spread or both, alpha-fetoprotein concentration, and Eastern Cooperative Oncology Group performance status. Dual primary endpoints were overall survival (superiority threshold at final overall survival analysis, one-sided p=0019; final analysis to occur after 532 events) and progression-free survival (superiority threshold one-sided p=0002; final analysis to occur after 571 events) in the intention-to-treat population. Results from the final analysis are reported. This study is registered with ClinicalTrials.gov, NCT03713593, and is active but not recruiting.Findings Between Jan 17, 2019, and April 28, 2020, of 1309 patients assessed, 794 were randomly assigned to lenvatinib plus pembrolizumab (n=395) or lenvatinib plus placebo (n=399). Median age was 660 years (IQR 570-720), 644 (81%) of 794 were male, 150 (19%) were female, 345 (43%) were Asian, 345 (43%) were White, 22 (3%) were multiple races, 21 (3%) were American Indian or Alaska Native, 21 (3%) were Native Hawaiian or other Pacific Islander, 13 (2%) were Black or African American, and 46 (6%) did not have available race data. Median follow up as of data cutoff for the final analysis (June 21, 2022) was 321 months (IQR 294-353). Median overall survival was 212 months (95% CI 190-236; 252 [64%] of 395 died) with lenvatinib plus pembrolizumab versus 190 months (172-217; 282 [71%] of 399 died) with lenvatinib plus placebo (hazard ratio [HR] 084; 95% CI 071-100; stratified log-rank p=0023). As of data cutoff for the progression-free survival final analysis (April 5, 2021), median progression-free survival was 82 months (95% CI 64-84; 270 events occurred [42 deaths; 228 progressions]) with lenvatinib plus pembrolizumab versus 80 months (63-82; 301 events occurred [36 deaths; 265 progressions]) with lenvatinib plus placebo (HR 087; 95% CI 073-102; stratified log-rank p=0047). The most common treatment-related grade 3-4 adverse events were hypertension (69 [17%] of 395 patients in the lenvatinib plus pembrolizumab group vs 68 [17%] of 395 patients) in the lenvatinib plus placebo group), increased aspartate aminotransferase (27 [7%] vs 17 [4%]), and diarrhoea (25 [6%] vs 15 [4%]). Treatment-related deaths occurred in four (1%) patients in the lenvatinib plus pembrolizumab group (due to gastrointestinal haemorrhage and hepatorenal syndrome [n=1 each] and hepatic encephalopathy [n=2]) and in three (1%) patients in the lenvatinib plus placebo group (due to gastrointestinal haemorrhage, hepatorenal syndrome, and cerebrovascular accident [n=1 each]).Interpretation In earlier studies, the addition of pembrolizumab to lenvatinib as first-line therapy for advanced hepatocellular carcinoma has shown promising clinical activity; however, lenvatinib plus pembrolizumab did not meet prespecified significance for improved overall survival and progression-free survival versus lenvatinib plus placebo. Our findings do not support a change in clinical practice.

A Single-Arm Phase Ib/II Study of Lenvatinib Plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma

A phase Ib/II study of the combination of lenvatinib (L) and eribulin (E) in advanced liposarcoma (LPS) and leiomyosarcoma (LMS) (LEADER): Efficacy updates.

Lenvatinib Plus PD-1 Inhibitors As First-Line Treatment in Patients with Unresectable Biliary Tract Cancer: A Single-Arm, Open-Label, Phase II Study

Advancing treatment efficacy: combined therapy of eribulin, anlotinib, and camrelizumab in advanced or metastatic retroperitoneal liposarcoma

Safety and Efficacy of Eribulin Plus Anlotinib in Patients with Advanced Soft Tissue Sarcoma (ERAS): A Multi-Center Phase II Study.

A pilot study of lenvatinib plus pembrolizumab in patients with advanced sarcoma.

Phase II Study of Eribulin plus Pembrolizumab in Metastatic Soft Tissue Sarcomas: Clinical Outcomes and Biological Correlates

Lenvatinib with or Without Concurrent Drug-Eluting Beads Transarterial Chemoembolization in Patients with Unresectable, Advanced Hepatocellular Carcinoma: A Real-World, Multicenter, Retrospective Study

LEAP-014: an Open-Label, Randomized, Phase 3 Study of First-Line Lenvatinib Plus Pembrolizumab Plus Chemotherapy in Esophageal Squamous Cell Carcinoma

LEAP-012 Trial in Progress: Transarterial Chemoembolization (TACE) with or Without Lenvatinib Plus Pembrolizumab for Intermediate-Stage Hepatocellular Carcinoma (HCC)

LEAP-014: First-Line Lenvatinib + Pembrolizumab + Chemotherapy in Advanced/metastatic Esophageal Squamous Cell Carcinoma

Lenvatinib Plus Pembrolizumab Versus Lenvatinib Plus Placebo for Advanced Hepatocellular Carcinoma (LEAP-002): a Randomised, Double-Blind, Phase 3 Trial.

LBA34 Primary Results from the Phase III LEAP-002 Study: Lenvatinib Plus Pembrolizumab Versus Lenvatinib As First-Line (1L) Therapy for Advanced Hepatocellular Carcinoma (Ahcc)

First-line Lenvatinib Plus Pembrolizumab Plus Chemotherapy in Esophageal Squamous Cell Carcinoma: LEAP-014 Trial in Progress.

A Phase 1b Study of Lenvatinib plus Pembrolizumab in Patients with Unresectable Hepatocellular Carcinoma: Extended Analysis of Study 116

Lenvatinib plus pembrolizumab versus lenvatinib alone as first-line therapy for advanced hepatocellular carcinoma: Longer-term efficacy and safety results from the phase 3 LEAP-002 study.

Abstract No. 37 LEAP-012 Trial in Progress: Pembrolizumab, Lenvatinib, and Transarterial Chemoembolization Combination Therapy for Intermediate-Stage Hepatocellular Carcinoma Not Amenable to Curative Treatment

Lenvatinib, sintilimab plus transarterial chemoembolization for advanced stage hepatocellular carcinoma: A phase II study

Randomized Phase 3 LEAP-012 Study: Transarterial Chemoembolization With or Without Lenvatinib Plus Pembrolizumab for Intermediate-Stage Hepatocellular Carcinoma Not Amenable to Curative Treatment

Efficacy of Eribulin Administered in Combination with an Immune Checkpoint Inhibitor (ICI) and Anlotinib As Salvage Treatment for Patients (pts) with Advanced Adult Soft Tissue Sarcoma (STS)

Efficacy and safety analysis of anlotinib combined with etoposide plus cisplatin/carboplatin as first-line therapy for extensive-stage small cell lung cancer (SCLC): The final results from a phase II single-arm trial.